Chronic Myelogenous Leukemia: New Targeted Therapies Take Aim at Gleevec

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Introduction
• Disease Overview
  • Etiology and Pathophysiology
    • BCR-ABL-Positive Patients
    • BCR-ABL-Negative Patients
  • Diagnosis and Classifi cation
  • Patient Population, Symptoms, and Disease Progression
• Current Therapies
  • Drug Therapies
    • Novartis' s Gleevec
    • Novartis' s Tasigna
    • Bristol-Myers Squibb' s Sprycel
    • Interferon-Alpha
    • Generic Chemotherapeutic Agents
  • Progenitor Stem Cell Transplantation
    • Myeloablative Regimens
    • Allogenic Progenitor Stem Cell Transplantation
    • Autologous Progenitor Stem Cell Transplantation
• Emerging Therapies
  • Wyeth' s Bosutinib (SKI-606)
  • Novartis' s Panobinostat (LBH-589)
  • ChemGenex Pharmaceuticals' Omacetaxine Mepesuccinate
• 2008 Statistics and Market Outlook

Tables

• 1. Laboratory Features Characteristic of Chronic Myelogenous Leukemia
• 2. Poor Prognostic Factors for Chronic-Phase Chronic Myelogenous Leukemia
• 3. Commonly Used Current Therapies in the Treatment of Chronic Myelogenous Leukemia
• 4. Emerging Therapies for Chronic Myelogenous Leukemia
• 5. 2008 Worldwide Chronic Myelogenous Leukemia Market

Figures

• 1. The Philadelphia-Chromosome
• 2. Prevalent, Diagnosed Cases of Chronic Myelogenous Leukemia in the Major Pharmaceutical Markets, 2008 and 2013